CURAGEN, TOPOTARGET LAUNCH PXD101 TRIAL

A A

CuraGen and TopoTarget have begun patient dosing in a Phase I clinical trial evaluating the safety and tolerability of PXD101, a small molecule histone deacetylase (HDAC) inhibitor, in combination with cis-retinoic acid for the treatment of patients with advanced solid tumors.

The Phase I trial is an open-label, dose-escalation study being. The study aims to establish the maximum tolerated dose (MTD) and safety profile of PXD101 in combination with cis-retinoic acid for patients with advanced solid tumors, which are refractory to standard therapies or for which no standard treatment exists. Up to 24 patients will be enrolled in the study and each will receive PXD101 and cis-retinoic acid in continuous three week cycles until disease progression.